{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T10:30:37Z","timestamp":1782556237307,"version":"3.54.5"},"reference-count":64,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>I started my research career (in 1965) on interferon by identifying polyacrylic acid (PAA) as an interferon inducer. Poly(I).poly(C), discovered by Maurice Hilleman\u2019s group, proved to be more potent as an interferon inducer, and through its mRNA, we were able to clone and express human \u03b2-interferon. The discovery of the reverse transcriptase (RT) by Temin and Baltimore (in 1970) brought me to the detection of suramin as a powerful RT inhibitor and enabled Sam Broder and his colleagues to identify suramin as the first inhibitor of HIV replication. In this capacity, it was subsequently superseded by AZT and other 2\u2032,3\u2032-dideoxynucleoside (ddN) analogs, including d4T. In collaboration with Anton\u00edn Hol\u00fd, we discovered several acyclic nucleoside phosphonates as potent inhibitors of both HIV and HBV (hepatitis B virus) replication. In collaboration with Paul Janssen, we identified various non-nucleoside RT inhibitors (NNRTIs) of HIV-1 replication. Of the nucleotide RT inhibitors (NtRTTs), tenofovir emerged as the most promising congener. It was derivatized to its oral prodrugs TDF and TAF. To enhance their efficacy, they were combined with other anti-HIV drugs, and two of them were pursued (and found efficacious) in the Pre-Exposure Prophylaxis (PrEP) of HIV infections.<\/jats:p>","DOI":"10.3390\/v17020222","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T04:15:41Z","timestamp":1738728941000},"page":"222","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sixty Years at the Rega Institute"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-8890","authenticated-orcid":false,"given":"Erik","family":"De Clercq","sequence":"first","affiliation":[{"name":"Rega Institute for Medical Research, KU Leuven, Herestraat 49, B-3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus interference. I. The interferon","volume":"147","author":"Isaacs","year":"1957","journal-title":"Proc. R. Soc. Lond. B Biol. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/1821073a0","article-title":"Mode of action of interferon","volume":"182","author":"Isaacs","year":"1958","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1056\/NEJM196712142772403","article-title":"Interferon induction in man by a synthetic polyanion of defined composition","volume":"277","author":"Merigan","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM196704202761608","article-title":"Interferons of mice and men","volume":"276","author":"Merigan","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1128\/jvi.2.9.878-885.1968","article-title":"Antiviral activity of polyacrylic and polymethacrylic acids. I. Mode of action in vitro","volume":"2","author":"Billiau","year":"1968","journal-title":"J. Virol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1128\/jvi.2.9.886-893.1968","article-title":"Antiviral activity of polyacrylic and polymethacrylic acids. II. Mode of action in vivo","volume":"2","author":"Billiau","year":"1968","journal-title":"J. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1128\/am.16.9.1314-1319.1968","article-title":"Effect of interferon, polyacrylin acid, and polymethacrylic acid on tail lesions on mice infected with vaccinia virus","volume":"16","year":"1968","journal-title":"Appl. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1073\/pnas.58.3.1004","article-title":"Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes","volume":"58","author":"Field","year":"1967","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1126\/science.173.3993.260","article-title":"Antiviral activity of polyribocytidylic acid in cells primed with polyriboinosinic acid","volume":"173","year":"1971","journal-title":"Science"},{"key":"ref_10","first-page":"1345","article-title":"Role of interferon in the protective effect of the double- stranded polyribonucleotide against murine tumors induced by Moloney sarcoma virus","volume":"47","year":"1971","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/285542a0","article-title":"Isolation and structure of a human fibroblast interferon gene","volume":"285","author":"Derynck","year":"1980","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/287193a0","article-title":"Expression of human fibroblast interferon gene in Escherichia coli","volume":"287","author":"Derynck","year":"1980","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1073\/pnas.79.9.2768","article-title":"Secretory proteins induced in human fibroblasts under conditions used for the production of interferon beta","volume":"79","author":"Content","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/2261211a0","article-title":"RNA-dependent DNA polymerase in virions of Rous sarcoma virus","volume":"226","author":"Temin","year":"1970","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/2261209a0","article-title":"RNA-dependent DNA polymerase in virions of RNA tumour viruses","volume":"226","author":"Baltimore","year":"1970","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0304-3835(79)90017-X","article-title":"Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor viruses","volume":"8","year":"1979","journal-title":"Cancer Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1126\/science.6091268","article-title":"Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III","volume":"226","author":"Mitsuya","year":"1984","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(85)90002-9","article-title":"Effects of suramin on HTLV-III\/LAV infection presenting as Kaposi\u2019s sarcoma or AIDS-related complex: Clinical pharmacology and suppression of virus replication in vivo","volume":"2","author":"Broder","year":"1985","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1073\/pnas.82.20.7096","article-title":"3\u2019-Azido-3\u2019-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III\/lymphadenopathy-associated virus in vitro","volume":"82","author":"Mitsuya","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/0006-2952(80)90149-5","article-title":"Antiviral, antimetabolic and antineoplastic activities of 2\u2019- or 3\u2019-amino or -azido-substituted deoxyribonucleosides","volume":"29","author":"Balzarini","year":"1980","journal-title":"Biochem. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3181\/00379727-137-35627","article-title":"Moloney sarcoma virus-induced tumors in mice: Inhibition or stimulation by (poly rI)\u00b7(poly rC)","volume":"137","author":"Merigan","year":"1971","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8333","DOI":"10.1073\/pnas.83.21.8333","article-title":"Phosphorylation of 3\u2019-azido-3\u2019-deoxythymidine and selective interaction of the 5\u2019-triphosphate with human immunodeficiency virus reverse transcriptase","volume":"83","author":"Furman","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1073\/pnas.83.6.1911","article-title":"Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III\/lymphadenopathy-associated virus (HTLV-III\/LAV) by 2\u2019,3\u2019-dideoxynucleosides","volume":"83","author":"Mitsuya","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0006-291X(87)90460-8","article-title":"Both 2\u2019,3\u2019-dideoxythymidine and its 2\u2019,3\u2019-unsaturated derivative (2\u2019,3\u2019-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro","volume":"142","author":"Baba","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1016\/0006-2952(87)90287-5","article-title":"Potent and selective in vitro activity of 3\u2019-deoxythymidin-2\u2019-ene (3\u2019-deoxy-2\u2019,3\u2019-didehydrothymidine) against human immunodeficiency virus","volume":"36","author":"Lin","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1128\/AAC.31.6.907","article-title":"Inhibitory effect of 2\u2019,3\u2019-didehydro-2\u2019,3\u2019-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus","volume":"31","author":"Hamamoto","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1073\/pnas.76.6.2947","article-title":"(E)-5-(2-Bromovinyl)-2\u2019-deoxyuridine: A potent and selective anti-herpes agent","volume":"76","author":"Descamps","year":"1979","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1073\/pnas.74.12.5716","article-title":"Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine","volume":"74","author":"Elion","year":"1977","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/272583a0","article-title":"9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group","volume":"272","author":"Schaeffer","year":"1978","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/bmj.281.6249.1178","article-title":"Oral (E)-5-(2-bromovinyl)-2\u2019-deoxyuridine in severe herpes zoster","volume":"281","author":"Degreef","year":"1980","journal-title":"Br. Med. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/jmv.1890460315","article-title":"Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: A randomized double-blind trial","volume":"46","author":"Wutzler","year":"1995","journal-title":"J. Med. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1126\/science.200.4341.563","article-title":"(S)-9-(2,3-dihydroxypropyl)adenone: An aliphatic nucleoside analog with broad-spectrum antiviral activity","volume":"200","author":"Descamps","year":"1978","journal-title":"Science"},{"key":"ref_33","first-page":"467","article-title":"A novel selective broad-spectrum anti-DNA virus agent","volume":"323","author":"Rosenberg","year":"1986","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0166-3542(87)80004-9","article-title":"Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines","volume":"8","author":"Sakuma","year":"1987","journal-title":"Antiviral Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1128\/AAC.32.12.1839","article-title":"(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication","volume":"32","author":"Snoeck","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7326\/0003-4819-126-4-199702150-00001","article-title":"Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial","volume":"126","author":"Lalezari","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jmv.1890410312","article-title":"Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice","volume":"41","author":"Neyts","year":"1993","journal-title":"J. Med. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nature04295","article-title":"Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection","volume":"439","author":"Stittelaar","year":"2006","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/jmv.1890450221","article-title":"Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine","volume":"45","author":"Snoeck","year":"1995","journal-title":"J. Med. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/(SICI)1096-9071(199803)54:3<219::AID-JMV13>3.0.CO;2-C","article-title":"Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine]","volume":"54","author":"Snoeck","year":"1998","journal-title":"J. Med. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/(SICI)1096-9071(200002)60:2<205::AID-JMV16>3.0.CO;2-8","article-title":"Cidofovir, a new approach for the treatment of Cervix Intraepithelial Neoplasia Grade III (CIN III)","volume":"60","author":"Snoeck","year":"2000","journal-title":"J. Med. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"102528","DOI":"10.1016\/j.tmaid.2022.102528","article-title":"Therapeutic strategies for human poxvirus infections: Monkeypox (mpox), smallpox, molluscipox, and orf","volume":"52","author":"Jiang","year":"2023","journal-title":"Travel. Med. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1128\/AAC.32.7.1025","article-title":"Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents","volume":"32","author":"Pauwels","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1073\/pnas.86.1.332","article-title":"Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent","volume":"86","author":"Balzarini","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/AAC.37.2.332","article-title":"Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: Potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine","volume":"37","author":"Balzarini","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/AAC.42.7.1568","article-title":"Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice","volume":"42","author":"Naesens","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1128\/AAC.42.3.612","article-title":"Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA","volume":"42","author":"Robbins","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1128\/AAC.49.5.1898-1906.2005","article-title":"Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue","volume":"49","author":"Lee","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bcp.2017.11.023","article-title":"Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections","volume":"153","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/343470a0","article-title":"Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives","volume":"343","author":"Pauwels","year":"1990","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1073\/pnas.88.4.1451","article-title":"An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk][1,4-benzodiazepin-2(1H)-one and -thione derivatives","volume":"88","author":"Debyser","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1073\/pnas.90.5.1711","article-title":"Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of a-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase","volume":"90","author":"Pauwels","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/0006-291X(89)92756-3","article-title":"Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative","volume":"165","author":"Baba","year":"1989","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1021\/jm00132a002","article-title":"A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine","volume":"32","author":"Miyasaka","year":"1989","journal-title":"J. Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1073\/pnas.88.6.2356","article-title":"Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase","volume":"88","author":"Baba","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0026-895X(25)11080-8","article-title":"Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives","volume":"39","author":"Baba","year":"1991","journal-title":"Mol. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cbdv.200490012","article-title":"Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Past, present and future","volume":"1","year":"2004","journal-title":"Chem. Biodivers."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nsb0595-407","article-title":"Structure of HIV-1 RT\/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors","volume":"2","author":"Ding","year":"1995","journal-title":"Nat. Struct. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1128\/AAC.38.4.688","article-title":"Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro","volume":"38","author":"Baba","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1021\/jm040840e","article-title":"In search of a novel anti-HIV drug: Multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)","volume":"48","author":"Janssen","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"23","DOI":"10.33696\/immunology.2.015","article-title":"Tenofovir at the crossroad of the therapy and prophylaxis of HIV and HBV infections","volume":"2","year":"2020","journal-title":"J. Cell. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1126\/science.270.5239.1197","article-title":"Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine","volume":"270","author":"Tsai","year":"1995","journal-title":"Science"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-Yearly Lenacapavir or Daily F\/TAF for HIV Prevention in Cisgender Women","volume":"391","author":"Bekker","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/jac\/dkae115","article-title":"Ultra-rapid selection of the N74D capsid inhibitor resistance mutation after 3 weeks on lenacapavir","volume":"79","author":"Wirden","year":"2024","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/2\/222\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:26:55Z","timestamp":1760027215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/2\/222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":64,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["v17020222"],"URL":"https:\/\/doi.org\/10.3390\/v17020222","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]}}}